A Rabbit Model for Testing Helper-Dependent Adenovirus-Mediated Gene Therapy for Vein Graft Atherosclerosis.

A Rabbit Model for Testing Helper-Dependent Adenovirus-Mediated Gene Therapy for Vein Graft Atherosclerosis.
复制标题

DOI:
10.1016/j.omtm.2017.09.004
复制
发表时间:
2017-12-15
期刊:
Molecular therapy. Methods & clinical development
影响因子:
--
通讯作者:
Dichek DA
Dichek DA
中科院分区:
其他
文献类型:
--
作者:
Bi L;Wacker BK;Bueren E;Ham E;Dronadula N;Dichek DA

文献摘要

参考文献

被引文献

相似文献

冠状动脉旁路移植静脉是治疗人类动脉粥样硬化的主要手段。不幸的是,静脉移植物的长期通畅性受到加速的动脉粥样硬化的限制。针对静脉移植物壁的基因治疗是预防静脉移植物动脉粥样硬化的一种有前途的方法。由于辅助依赖性腺病毒(HDAd)有效地转导移植静脉,并赋予长期的转基因表达,HDAd是一个很好的候选人提供静脉移植靶向基因治疗。我们在脂肪喂养的兔子中建立了静脉移植物动脉粥样硬化模型,并证明了移植物转导后HDAd基因组的长期(≥20周)持续存在。该模型能够定量单个移植物上的静脉移植物血流动力学、壁结构、脂质积聚、细胞构成、载体持久性和炎症标记物。时程实验确定转导后12周为测量基因治疗对脂质和巨噬细胞积累的关键变量的功效的最佳时间。我们还使用饲料喂养的兔子来测试静脉移植物中的HDAd输注是否促进内膜生长和炎症。HDAd不增加内膜生长,但具有中度但显著的促炎作用。静脉移植物动脉粥样硬化模型将用于测试HDAd介导的基因治疗;然而,在开发HDAd作为静脉移植物疾病的治疗中,HdAd的促炎作用仍然是一个问题。
Coronary artery bypass vein grafts are a mainstay of therapy for human atherosclerosis. Unfortunately, the long-term patency of vein grafts is limited by accelerated atherosclerosis. Gene therapy, directed at the vein graft wall, is a promising approach for preventing vein graft atherosclerosis. Because helper-dependent adenovirus (HDAd) efficiently transduces grafted veins and confers long-term transgene expression, HDAd is an excellent candidate for delivery of vein graft-targeted gene therapy. We developed a model of vein graft atherosclerosis in fat-fed rabbits and demonstrated long-term (≥20 weeks) persistence of HDAd genomes after graft transduction. This model enables quantitation of vein graft hemodynamics, wall structure, lipid accumulation, cellularity, vector persistence, and inflammatory markers on a single graft. Time-course experiments identified 12 weeks after transduction as an optimal time to measure efficacy of gene therapy on the critical variables of lipid and macrophage accumulation. We also used chow-fed rabbits to test whether HDAd infusion in vein grafts promotes intimal growth and inflammation. HDAd did not increase intimal growth, but had moderate—yet significant—pro-inflammatory effects. The vein graft atherosclerosis model will be useful for testing HDAd-mediated gene therapy; however, pro-inflammatory effects of HdAd remain a concern in developing HDAd as a therapy for vein graft disease.
DOI: 10.1089/hgtb.2013.199
发表时间: 2014-04-01
影响因子: --
作者:
Du, Liang;Zhang, Jingwan;Dichek, David A.
通讯作者: Dichek, David A.
DOI: 10.1038/mt.2011.133
发表时间: 2011-10-01
期刊: MOLECULAR THERAPY
影响因子: 12.4
作者:
Flynn, Rowan;Qian, Kun;Dichek, David A.
通讯作者: Dichek, David A.
DOI: 10.1161/01.atv.0000197795.56960.64
发表时间: 2006-02-01
影响因子: 8.7
作者:
de Nooijer, R;Verkleij, CJN;Biessen, EAL
通讯作者: Biessen, EAL
DOI: 10.1089/hum.2016.134
发表时间: 2017-03-01
期刊: HUMAN GENE THERAPY
影响因子: 4.2
作者:
Dronadula, Nagadhara;Wacker, Bradley K.;Dichek, David A.
通讯作者: Dichek, David A.
DOI: 10.1089/hum.2014.084
发表时间: 2015-01-01
期刊: HUMAN GENE THERAPY
影响因子: 4.2
作者:
Du, Liang;Zhang, Jingwan;Dichek, David A.
通讯作者: Dichek, David A.